FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula IA, IC or IB, or a pharmaceutically acceptable salt thereof, wherein the radicals R1, R2a, R2b, R2c, R2d, R2e, R15, R20 are given in the claims. Invention also relates to a process for the preparation of a compound of formula IA, comprising (i) reacting guanidine of formula A-11 and 1,3-dielectrophil to obtain 4-hydroxypyrimidin-2-yl-amine of formula A-13; (ii) converting A-13 to the 4-leaving-pyrimidine-2-yl-amine group of formula A-14; and (iii) reacting said 4-leaving-pyrimidin-2-yl-amine A-14 and aryl or heteroarylamine, A-3; where Z1 is CH or CR2, where R2 such as defined for R2a-e in p. 1; and LG is halogen, arylsulfonate, alkyl sulfonate, phosphonate, azide or -S(O)0-2Re. 
, 
, 
. 
, 
, 
.
EFFECT: compounds of the invention are intended to inhibit the activity of the JAK3 kinase.
22 cl, 4 tbl, 12 ex
диэлектрофил - dielectrophil
| Title | Year | Author | Number |
|---|---|---|---|
| 2,4-PYRIMIDINDIAMINE COMPOUNDS HAVING EFFECT IN CASE OF AUTOIMMUNE DISORDERS | 2004 |
|
RU2356901C2 |
| ANILINE PYRIMIDINE DERIVATIVES AND USE THEREOF | 2016 |
|
RU2734849C2 |
| AMINOPYRIMIDINE DERIVATIVES AS LEUCINE-RICH REPEAT KINASE 2 (LRRK2) MODULATORS | 2012 |
|
RU2651544C2 |
| 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | 2020 |
|
RU2822388C2 |
| MACROHETEROCYCLIC NUCLEOSIDE DERIVATIVES AND ANALOGUES THEREOF, PRODUCTION AND USE | 2017 |
|
RU2731385C1 |
| NOVEL 4-AMINO-N-HYDROXYBENZAMIDES AS HDAC INHIBITORS FOR TREATING CANCER | 2012 |
|
RU2591190C2 |
| PYRIMIDINE DERIVATIVES | 2008 |
|
RU2455994C2 |
| COMPOUNDS OF FORMULA (I) AND FORMULA (A), PHARMACEUTICAL COMPOSITION, MEDICINAL PRODUCT, USE AND METHOD OF OBTAINING COMPOUNDS OF FORMULA (I) | 2018 |
|
RU2822758C2 |
| METHODS FOR TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH USE OF 2,4-PYRIMIDINEDIAMINE | 2013 |
|
RU2659777C2 |
| HETEROARYL COMPOUNDS AND USE THEREOF | 2009 |
|
RU2734822C2 |
